Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF(V600)-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

PURPOSE: Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is more effective in BRAF(V600)-mutant melanoma than single-agent BRAF inhibitors. This study assessed the safety and efficacy of dabrafenib and trametinib in patients who had...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Clin Oncol
मुख्य लेखकों: Johnson, Douglas B., Flaherty, Keith T., Weber, Jeffrey S., Infante, Jeffrey R., Kim, Kevin B., Kefford, Richard F., Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Sharfman, William H., McWilliams, Robert R., Sznol, Mario, Lawrence, Donald P., Gibney, Geoffrey T., Burris, Howard A., Falchook, Gerald S., Algazi, Alain, Lewis, Karl, Long, Georgina V., Patel, Kiran, Ibrahim, Nageatte, Sun, Peng, Little, Shonda, Cunningham, Elizabeth, Sosman, Jeffrey A., Daud, Adil, Gonzalez, Rene
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Clinical Oncology 2014
विषय:
ORIGINAL REPORTS
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226803/
https://ncbi.nlm.nih.gov/pubmed/25287827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.3535
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन